OncLive TV

OncLive® TV is an editorial video program featuring one-on-one live and/or virtual interviews with key opinion leaders in the oncology field for their expert insight on breaking news, regulatory updates, practice-changing data presented at medical meetings, and other pivotal topics in a cancer specialty, including breast cancer, lung cancer, genitourinary cancers, gastrointestinal cancers, gynecologic cancers, and hematologic cancers.

Dr. Kurtzberg on Long-term OS for Remestemcel-L in Pediatric Steroid-Refractory aGVHD

February 28th 2023

Joanne Kurtzberg, MD, discusses the long-term survival outcomes from an observational cohort study evaluating remestemcel-L in pediatric patients with steroid-refractory acute graft-vs-host disease.

Dr. Nguyen on Primary Analysis of the FORMULA-509 Trial in Prostate Cancer

February 28th 2023

Paul L. Nguyen, MD, discusses primary findings from the phase 2 FORMULA-509 trial in prostate cancer.

Dr. Sonpavde on Predicting 5-year Survival Outcomes in MIBC Using Neural Network Analysis

February 28th 2023

Guru P. Sonpavde, MD, discusses the methodology and key results from an analysis of the Cancer Genome Atlas in muscle-invasive bladder cancer.

Dr. Giralt on the Evaluation of Ide-cel in Triple-Class Exposed R/R Myeloma

February 27th 2023

Sergio A. Giralt, MD, discusses the investigation of idecabtagene vicleucel vs standard-of-care regimens in patients with triple-class exposed relapsed/refractory multiple myeloma in the phase 3 Karmma-3 trial.

Dr. Jain on Transplantation from Haploidentical Donors in Myelofibrosis

February 27th 2023

Tania Jain, MBBS, discusses post-transplant cyclophosphamide-based transplantation from haploidentical donors in myelofibrosis.

Dr. Beitinjaneh on the Evaluation of Tabelecleucel in EBV+ Hematologic Malignancies

February 27th 2023

Amer M. Beitinjaneh, MD, discusses updated results from phase 3 ALLELE trial investigating the use of tabelecleucel in Epstein-Barr Virus–positive post-transplant lymphoproliferative disease following allogeneic hematopoietic stem cell transplant or solid organ transplant after failure of rituximab with or without chemotherapy.

Dr. Sanjana on the Use of Whole-Exome Sequencing to Predict Immunotherapy Response in Advanced Tumors

February 27th 2023

Neville E. Sanjana, PhD, discusses a study on the predictive utility of the Cancer Immunotherapy Response CLassifiEr in advanced-stage cancers.

Dr. Van Cutsem on Primary Findings from the SPOTLIGHT and GLOW Trials in Metastatic Gastric Cancer

February 27th 2023

Eric Van Cutsem, MD, PhD, discusses primary efficacy and safety findings from the phase 3 SPOTLIGHT and GLOW trials investigating the monoclonal antibody zolbetuximab in metastatic gastric cancer.

Dr. Sauter on Questions Surrounding Novel Therapies in Hematologic Malignancies

February 24th 2023

Craig Sauter, MD, discusses prominent questions surrounding new and emerging therapies in the treatment of patients with hematologic malignancies.

Dr. Wang on Contraindications to Hypomethylating Therapy in Older Patients With AML

February 24th 2023

Eunice Wang, MD, discusses reasons why some older patients with acute myeloid leukemia may not be eligible to receive hypomethylating therapy and highlights ongoing investigations within this older patient population

Dr. Chao on the Study of PD-L1 Inhibitors with NSCLC

February 24th 2023

Yvonne Chao, MD, PhD, discusses the study of various PD-L1 inhibitors in patients with non–small cell lung cancer.

Dr. Ehrhardt on Factors Associated with Late Mortality in Survivors of Childhood Cancer

February 24th 2023

Matthew J. Ehrhardt, MD, MS, discusses the link between modifiable chronic health conditions and social determinants of health with late mortality for survivors of childhood cancer.

Dr. Harding on Future Directions in the Treatment of Advanced Biliary Tract Cancers

February 24th 2023

James Harding, MD, discusses future directions in the treatment of patients with advanced biliary tract cancer.

Dr. McArthur on the Implications of the ASCENT Trial in TNBC

February 24th 2023

Heather Lynn McArthur, MD, MPH, discusses the implications of the phase 3 ASCENT trial in patients with advanced triple-negative breast cancer.

Dr. Amandeep Salhotra on the Efficacy and Safety of Orca-Q in GVHD

February 24th 2023

Amandeep Salhotra, MD, discusses efficacy data from a phase 1 trial of Orca-Q in acute and chronic graft-vs-host disease.

Dr. Cortes on Better Understanding Areas of Interest in ALL

February 24th 2023

Jorge E. Cortes, MD, discusses important questions in acute lymphoblastic leukemia to address, such as improved understanding of the role of allogenic stem cell transplant and the use of tyrosine kinase inhibitor combinations.

Dr. Barber on the Role of Molecular Profiling for Treatment Considerations in Endometrial Cancer

February 23rd 2023

Emma L. Barber, MD, discusses the role of molecular profiling for treatment considerations in patients with endometrial cancer.

Dr. Frank on the Rationale for CD22-Targeted CAR T-cell Therapy After CD19 Relapse in LBCL

February 23rd 2023

Matthew Frank, MD, PhD, discusses the rationale for investigating CD22-directed CAR-T cell therapy in adult patients with large B-cell lymphoma who relapsed after or were refractory to CD19-directed CAR T-cell therapy.

Dr. Patil on Unmet Needs With the Use of Immunotherapy in NSCLC

February 23rd 2023

Pradnya D. Patil, MD, FACP, discusses unmet needs that remain to be addressed with the use of immunotherapy in patients with non–small cell lung cancer.

Dr. Kim on Tislelizumab in Advanced ESCC

February 23rd 2023

Sunnie Kim, MD, contextualizes the use of tislelizumab as a frontline treatment option in advanced esophageal squamous cell carcinoma.